Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 17/20 | 0.64 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.63 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.63 |
| ▸ | UMPS | P11172 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18852578 | 1.00 | NT5E (0.65) | NT5EP2RY2P2RY6P2RY4UMPS | |
| SCHEMBL15810654 | 1.00 | NT5E (0.65) | NT5EP2RY2P2RY6P2RY4UMPS | |
| SCHEMBL32671744 | 1.00 | NT5E (0.65) | NT5EP2RY2P2RY6P2RY4UMPS | |
| SCHEMBL29185234 | 0.90 | NT5E (0.67) | NT5EP2RY2P2RY6P2RY4 | |
| SCHEMBL14929505 | 0.90 | NT5E (0.67) | NT5EP2RY2P2RY6P2RY4 | |
| SCHEMBL18574264 | 0.90 | NT5E (0.67) | NT5EP2RY2P2RY6P2RY4 | |
| SCHEMBL14946397 | 0.90 | NT5E (0.67) | NT5EP2RY2P2RY6P2RY4 | |
| SCHEMBL31685495 | 0.90 | UMPS (0.77) | NT5EP2RY2P2RY6P2RY4UMPS | |
| SCHEMBL22371486 | 0.89 | UMPS (0.79) | P2RY2P2RY6P2RY4UMPS | |
| SCHEMBL15810653 | 0.85 | UMPS (0.62) | NT5EP2RY2P2RY6P2RY4UMPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885P2RY2 2899/4885P2RY6 1545/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885P2RY2 2899/4885P2RY6 1545/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885P2RY2 2899/4885P2RY6 1545/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885P2RY2 2899/4885P2RY6 1545/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | NT5E 67/4885P2RY2 2786/4885P2RY6 2112/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | NT5E 67/4885P2RY2 2786/4885P2RY6 2112/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885P2RY2 2899/4885P2RY6 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.